Login to Your Account

Pharma: Clinic Roundup

Friday, August 2, 2013
Boehringer Ingelheim GmbH, of Ingelheim, Germany, said data from the LUX-Lung trial program, investigating afatinib in patients with advanced non-small-cell lung cancer (NSCLC), have been published in the Journal of Clinical Oncology.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription